U.S. Industrials Stock News

Xylem (NYSE:XYL) has authorized a new share repurchase program of up to $1.5b. The program allows the company to buy back shares opportunistically over time. The announcement comes with Xylem shares recently trading around $129.56. Xylem, trading on the NYSE under the ticker XYL, is moving ahead with a sizeable $1.5b buyback plan at a share price of about $129.56. Over the past 3 years, the stock has returned 29.3%, and 37.1% over 5 years, which gives context for how management is choosing...

Willdan Group (WLDN) capped FY 2025 with fourth quarter revenue of US$173.7 million and basic EPS of US$1.28, while trailing twelve month revenue reached US$681.6 million with EPS of US$3.63 as earnings over the last year were reported to have grown 131.8%. Over the past six quarters the company has seen quarterly revenue range from US$144.1 million to US$182.0 million, with basic EPS between US$0.33 and US$1.28. This sets up a story where improving net profit margin to 7.7% from 4% and high...

Shift4 Payments (FOUR) has wrapped up FY 2025 with Q4 revenue of US$1.2b and basic EPS of US$0.37, alongside net income of US$25m that keeps the spotlight firmly on how efficiently each transaction is translating into profit. The company has seen quarterly revenue move from US$909.2m in Q3 2024 to US$848.3m in Q1 2025 and then up to US$1.2b in Q4 2025, while basic EPS shifted from US$0.78 in Q3 2024 to US$0.24 in Q1 2025 and US$0.37 in the latest quarter, setting the stage for investors to...

Starz Entertainment (STRZ) opened Q3 2026 with revenue of US$322.8 million and a basic EPS loss of US$1.24, with trailing twelve month EPS at a loss of US$16.16 on revenue of US$1.3 billion. Over recent quarters, the company has seen quarterly revenue move from US$346.9 million in Q2 2025 to US$344.5 million in Q3 2025, US$330.6 million in Q4 2025, and then settle around US$320.3 million to US$322.8 million across the first three quarters of 2026, while basic EPS losses shifted between...

Xenon Pharmaceuticals (XENE) has put fresh numbers on the table for FY 2025, with first half revenue at US$7.5 million and a basic EPS loss of US$1.90, alongside a trailing twelve month EPS loss of US$4.36. The company has seen revenue move from US$0 in both halves of 2024 to US$7.5 million in the latest half. Basic EPS losses widened from US$1.36 and US$1.64 in the first and second halves of 2024 to US$1.90 most recently and a trailing twelve month net loss of US$345.91 million, keeping...

American Healthcare REIT (AHR) has wrapped up FY 2025 with Q4 revenue of US$604.1 million and basic EPS of US$0.06, rounding out a trailing twelve month picture that shows total revenue of about US$2.3 billion and basic EPS of US$0.42. Over the past few quarters the REIT has seen revenue move from US$540.2 million in Q4 2024 to US$604.1 million in Q4 2025, while quarterly EPS shifted from a loss of US$0.20 per share to a profit of US$0.06 per share. This sets up a year where investors will be...

GoodRx Holdings (GDRX) is back in focus after launching its Employer Direct platform to help companies reduce high-impact brand drug costs, alongside 2025 earnings, fresh 2026 guidance, and a cluster of analyst rating changes. See our latest analysis for GoodRx Holdings. GoodRx’s recent earnings update, 2026 revenue guidance and the Employer Direct launch have been followed by a sharp reset in sentiment, with a 7 day share price return of 24.29% decline and a 1 year total shareholder return...

Burford Capital (NYSE:BUR) rounded out FY 2025 with Q4 revenue of US$33.4 million and a basic EPS loss of US$0.17, as quarterly earnings swung back into the red despite a profitable first half. The company has seen quarterly revenue move from US$244.9 million and EPS of US$0.62 in Q3 2024 to US$178.0 million and EPS of US$0.40 in Q2 2025, and then to US$64.7 million with an EPS loss of US$0.09 in Q3 2025 before landing at the latest Q4 figures. This sets up a results season in which investors...

Tutor Perini’s FY 2025 Earnings Snapshot Tutor Perini (TPC) has wrapped up FY 2025 with fourth quarter revenue of US$1.5 billion and basic EPS of US$0.55, alongside trailing twelve month revenue of US$5.5 billion and EPS of US$1.53 that mark a clear shift from prior losses. The company has seen quarterly revenue move from US$1.1 billion and an EPS loss of US$1.51 in Q4 2024 to US$1.5 billion and EPS of US$0.55 in Q4 2025. Net income moved from a loss of US$79.4 million to a profit of US$28.8...

SBA Communications (SBAC) closed out FY 2025 with Q4 revenue of US$719.6 million and basic EPS of US$3.48, while trailing twelve month revenue came in at about US$2.8 billion with EPS of US$9.83. Over that same trailing period, net income excluding extra items moved from US$749.5 million to US$1.05 billion, and EPS tracked from US$6.96 to US$9.83, providing a view of how the top and bottom lines have been scaling together. For investors, the combination of higher net margin and a steady...

If you are wondering whether Thermon Group Holdings is still attractively priced or already reflecting most of its potential, you are in the right place for a valuation-focused look at the stock. The share price, last closing at US$50.78, comes with a mixed return profile, with a 0.5% decline over 7 days, a 16.9% gain over 30 days, 34.9% year to date, 72.1% over 1 year, 84.6% over 3 years and 136.7% over 5 years. Recent price action sits alongside ongoing news flow around Thermon Group...

AvePoint (AVPT) has just wrapped up FY 2025 with Q4 revenue of US$114.7 million and basic EPS of US$0.07, alongside net income of US$15.6 million. The company has seen quarterly revenue move from US$88.8 million in Q3 2024 to US$114.7 million in Q4 2025, while basic EPS shifted from a loss of US$0.09 in Q4 2024 to US$0.07 in Q4 2025, setting up a cleaner profitability profile across the trailing twelve months. Over that period, revenue reached US$419.5 million and basic EPS was US$0.17. With...

Fulgent Genetics (FLGT) just posted its FY 2025 numbers, with fourth quarter revenue of US$83.3 million and a basic EPS loss of US$0.76, alongside net income excluding extra items at a loss of US$23.4 million. The company has seen quarterly revenue move from US$76.2 million in Q4 2024 to US$83.3 million in Q4 2025, while basic EPS shifted from a loss of US$0.19 to a loss of US$0.76 over the same stretch. This sets up a results season where the key question is how much of that top line is...

D-Market Elektronik Hizmetler ve Ticaret (NasdaqGS:HEPS) has wrapped up FY 2025 with Q4 revenue of approximately ₺30.3b and a net loss of about ₺3.2b, capping a year in which trailing twelve month revenue reached roughly ₺84.7b alongside a total net loss of around ₺5.7b. The company reported quarterly revenue increasing from about ₺20.4b in Q4 2024 to ₺30.3b in Q4 2025, while quarterly net losses widened from roughly ₺724m to about ₺3.2b over the same period. EPS on a trailing twelve month...

MannKind (MNKD) has wrapped up FY 2025 with fourth quarter revenue of US$112 million and a basic EPS loss of US$0.05, setting a clear focal point for investors watching how its income statement is evolving. Over recent periods the company has seen revenue move from US$70 million in Q3 2024 to US$82 million in Q3 2025, while quarterly EPS has ranged from US$0.04 in Q1 2025 to a small profit of US$0.03 in Q3 2025 before this latest loss. This puts the spotlight firmly on how durable its margins...

OPKO Health (OPK) just closed out FY 2025 with Q4 revenue of US$148.45 million, basic EPS of a US$0.04 loss, and quarterly net income excluding extra items showing a loss of US$31.26 million, set against trailing twelve month revenue of US$606.88 million and a loss of US$225.68 million on the same basis. The company has seen quarterly revenue move from US$183.64 million and basic EPS of US$0.02 in Q4 2024 to US$148.45 million and basic EPS of a US$0.04 loss in Q4 2025, while trailing twelve...

Alexander & Baldwin (ALEX) has wrapped up FY 2025 with fourth quarter revenue of US$43.8 million and basic EPS of US$0.05, alongside trailing twelve month revenue of US$206.7 million and EPS of US$0.89. Over the last six quarters, the company has seen quarterly revenue move from US$63.2 million in Q4 2024 to US$56.8 million in Q1 2025 and down to US$43.8 million in Q4 2025, while quarterly EPS moved from US$0.18 to US$0.29 and then US$0.05. This sets up a mixed backdrop for a stock trading at...

In February 2026, Camtek Ltd. reported its fourth‑quarter 2025 results, with sales rising to US$128.12 million and net income to US$35.9 million, alongside higher quarterly earnings per share than a year earlier. Despite full‑year 2025 net income dropping to US$50.72 million even as sales grew to US$496.07 million, management issued upbeat 2026 guidance, highlighting expected double‑digit revenue growth supported by a solid backlog and customer pipeline. We’ll now examine how Camtek’s...

Alta Equipment Group (ALTG) has reported fourth quarter FY 2025 revenue of US$509.1 million with a basic EPS loss of US$0.39, setting the tone for a year where the business stayed focused on scale while earnings remained in the red. The company has seen quarterly revenue move from US$448.8 million in Q3 2024 to US$498.1 million in Q4 2024, then to US$423.0 million in Q1 2025 and up to US$509.1 million in Q4 2025, while basic EPS over that stretch ranged from a loss of US$0.34 to a loss of...

TeraWulf (WULF) closed FY 2025 with Q4 revenue of US$35.8 million and a basic EPS loss of US$0.30, alongside a trailing twelve month revenue base of US$168.5 million and a full year EPS loss of US$1.66. Over the last six reported quarters, revenue has ranged from US$27.1 million in Q3 2024 to US$50.6 million in Q3 2025, while quarterly basic EPS losses have moved between US$0.05 and US$1.13. This gives investors a clear picture of a business still working through heavy losses. With trailing...

Hudson Pacific Properties (HPP) closed out FY 2025 with Q4 revenue of US$256.0 million and basic EPS of US$4.31 loss, while trailing twelve month revenue came in at US$831.1 million alongside a TTM basic EPS of US$12.81 loss. This gives investors a clear snapshot of pressure on per share results. Over recent periods, the company has seen quarterly revenue shift from US$208.8 million in Q4 2024 to US$256.0 million in Q4 2025, with basic EPS moving from a loss of US$8.28 per share to a loss of...

Delek US Holdings (DK) closed out FY 2025 with Q4 revenue of US$2,429.4 million and basic EPS of US$1.32, alongside net income from continuing operations of US$79.5 million. Over the past few quarters, revenue has moved between US$2,641.9 million and US$2,887 million while basic EPS has swung from a loss of US$2.78 in Q1 2025 to a profit of US$2.96 in Q3 2025 and then US$1.32 in Q4, highlighting the sensitivity of margins to refining conditions and product mix. See our full analysis for Delek...

C4 Therapeutics (CCCC) just posted its FY 2025 Q4 numbers, with revenue of US$11.0 million and a quarterly loss translating to basic EPS of US$0.18, set against a trailing twelve month loss of US$105.0 million and EPS of US$1.27 on revenue of US$35.9 million. Over recent quarters, the company has seen revenue move between US$5.2 million and US$15.4 million, while quarterly EPS has ranged from US$0.35 to US$0.49 and quarterly losses from US$24.7 million to US$34.6 million. The key question for...

Cigna Group (CI) has wrapped up FY 2025 with fourth quarter revenue of US$72.5b, basic EPS of US$4.67 and net income of US$1,234m, putting a clear spotlight on how the year’s strong headline numbers translate into underlying profitability. The company has seen quarterly revenue move from US$65.6b in Q4 2024 to US$72.5b in Q4 2025, with basic EPS shifting from US$5.13 to US$4.67 over the same period. Trailing 12 month EPS reached US$22.33 on net income of US$5,957m, highlighting a year in...